JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a ...

Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company’s quarterly revenue was up 126.5% compared to the same quarter last year.

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Blueprint Medicines (NASDAQ:BPMC) in the last three months. In the table below, you'll find ...

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $135.00. Andrew Fein’s rating is based on the strong ...

On Friday, Blueprint Medicines Corp (BPMC) stock saw a modest uptick, ending the day at $90.7 which represents a slight increase of $3.19 or 3.65% from the prior close of $87.51. The stock opened at ...

Blueprint Medicines (BPMC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni ...

It's been a good week for Blueprint Medicines Corporation ( NASDAQ:BPMC ) shareholders, because the company has just... Over the last 7 days, the United States market has dropped 1.6%, but over ...

On Tuesday, Blueprint Medicines Corp (BPMC) stock saw a modest uptick, ending the day at $83.4 which represents a slight increase of $0.63 or 0.76% from the prior close of $82.77. The stock opened at ...

Blueprint Medicines (BPMC) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...